Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Niels-Chr. G. Hansen (Odense C, Denmark), Niels-Chr. G. Hansen, Christian B. Laursen, Stefan S. Jeppesen, Erik Jakobsen. LATE-BREAKING ABSTRACT: Early relapse of non-small cell lung cancer (NSCLC) found after CNS-symptoms. Eur Respir J 2016; 48: Suppl. 60, 4854

Member's Comments

No comment yet.

Related content which might interest you: Screening for intracerebral metastasis in radically treated non-small cell lung cancer patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Differences in epidemiological and clinical features in non-small cell lung cancer (NSCLC) in never and ever smokers Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Prognostic impact of secondary malignancies in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Surveillance imaging and recurrence rates following surgery for non-small cell lung cancer (NSCLC). Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020 Preoperative FDG uptake on PET/CT predicts disease recurrence and survival in early stage non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017 Early versus late pulmonary rehabilitation (PR) following treatment for inoperable nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2013 –The best abstracts in extra-pulmonary features and pulmonary rehabilitation Year: 2013 Major changes in men with non-small-cell lung cancer (NSCLC) in 10 years: The KBP-2000-CPHG and KBP-2010-CPHG cohorts Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer Year: 2013 Comparing performance and cost of EBUS-TBNA versus other methods for diagnosis and staging of non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Decreased apoptosis rate of alveolar lymphocytes (AL) in patients with stage I-IIA non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Increased expression of WSX1 on alveolar lymphocytes (AL) in patients with early stage non-small cell lung cancer (NSCLC). Preliminary report Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Procalcitonin serum levels in patients with stage IV non-small cell lung cancer in first line of chemotherapy Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Outcomes of radical treatment of early stage non-small cell lung cancer Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer? Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS Source: International Congress 2016 – Endosonography: EBUS/EUS (B) Year: 2016